ARCT-810 - (LUNAR-OTC)

September 18, 2026: Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) announced a virtual presentation for September 23, 2026, at 4:30 p.m. ET to provide an overview of the ARCT-810 Phase 2 clinical program in ornithine transcarbamylase (OTC) deficiency and its mRNA liver therapeutics platform. The company said it will issue a press release summarizing the presentation before the call.

ARCT-810 is an intravenously administered investigational mRNA therapy intended to express functional OTC enzyme in the liver for patients with OTC deficiency. The release notes that ARCT-810 has EMA Orphan Medicinal Product Designation and an approved pediatric investigation plan, and FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for OTC deficiency.

The event will include Marshall Summar, M.D., described as a rare disease and OTC deficiency expert and a founding member and Executive Committee member of the NIH UCD Consortium. No clinical efficacy or safety data were disclosed in this announcement.